- Abstract:
-
Concomitant inhibition of multiple cancer-driving kinases is an established strategy to improve the durability of clinical responses to targeted therapies. The difficulty of discovering kinase inhibitors with an appropriate multitarget profile has, however, necessitated the application of combination therapies, which can pose major clinical development challenges. Epigenetic reader domains of the bromodomain family have recently emerged as new targets for cancer therapy. Here we report that s...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Accepted Manuscript
- Files:
-
-
(pdf, 3.1MB)
-
(pdf, 1.2MB)
-
(pdf, 338.9KB)
-
- Publisher copy:
- 10.1038/nchembio.1471
- Publisher:
- Nature Research Publisher's website
- Journal:
- Nature Chemical Biology Journal website
- Volume:
- 10
- Issue:
- 4
- Pages:
- 305-312
- Publication date:
- 2014-03-02
- DOI:
- EISSN:
-
1552-4469
- ISSN:
-
1552-4450
- URN:
-
uuid:1b14729e-56d8-4cf4-876a-9b465341762c
- Source identifiers:
-
450967
- Local pid:
- pubs:450967
- Language:
- English
- Keywords:
- Copyright holder:
- Nature America
- Copyright date:
- 2014
- Notes:
- © 2014 Nature America, Inc. This is the Accepted Manuscript version of the article. The final version is available online from Nature Chemical Biology at: https://doi.org/10.1038/nchembio.1471
Journal article
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
Actions
Access Document
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record